Overall antitumor activity was confirmed in two patients (7.1%): one patient with NSCLC [KRAS wild-type grade 3 (poorly differentiated)] who received dazostinag 2.5 mg in combination with pembrolizumab achieved a complete response (CR with a DOR of 9.3 months), and a second patient with SCCHN [p16-negative grade 3 (poorly differentiated) in the nasopharynx] who received dazostinag 5.0 mg in combination with pembrolizumab had a partial response (PR, maintained up to cycle eight/10 months; patient censored before progression or death). This evidence concerns the gene KRAS and non-small cell lung carcinoma.